Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 71 articles:
HTML format
Text format



Single Articles


    March 2017

  1. Correction: PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.
    Clin Cancer Res. 2017;23:1361.
    PubMed     Text format    


    February 2017
  2. CHUK MK, Chang JT, Theoret MR, Sampene E, et al
    FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma.
    Clin Cancer Res. 2017 Feb 24. pii: clincanres.0663.2016.
    PubMed     Text format     Abstract available


  3. BEHERA R, Kaur A, Webster MR, Kim S, et al
    Inhibition of age-related therapy resistance in melanoma by rosiglitazone-mediated induction of Klotho.
    Clin Cancer Res. 2017 Feb 23. pii: clincanres.0201.2017.
    PubMed     Text format     Abstract available


  4. EXLEY MA, Friedlander P, Alatrakchi N, Vriend L, et al
    Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: a Phase 1 Clinical Trial.
    Clin Cancer Res. 2017 Feb 13. pii: clincanres.0600.2016.
    PubMed     Text format     Abstract available


  5. BARONE A, Hazarika M, Theoret MR, Mishra-Kalyani P, et al
    FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma.
    Clin Cancer Res. 2017 Feb 8. pii: clincanres.0664.2016.
    PubMed     Text format     Abstract available


    January 2017
  6. DENIGER DC, Kwong ML, Pasetto A, Dudley ME, et al
    A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma.
    Clin Cancer Res. 2017;23:351-362.
    PubMed     Text format     Abstract available


  7. HAZARIKA M, Chuk MK, Theoret MR, Mushti S, et al
    U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab.
    Clin Cancer Res. 2017 Jan 13. pii: clincanres.0712.2016.
    PubMed     Text format     Abstract available


  8. BEAVER JA, Theoret MR, Mushti S, He K, et al
    FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma.
    Clin Cancer Res. 2017 Jan 10. pii: clincanres.0714.2016.
    PubMed     Text format     Abstract available


    November 2016
  9. GANNON P, Baumgaertner P, Huber A, Iancu EM, et al
    Rapid and continued T cell differentiation into long-term effector and memory stem cells in vaccinated melanoma patients.
    Clin Cancer Res. 2016 Nov 21. pii: clincanres.1708.2016.
    PubMed     Text format     Abstract available


  10. NAGARAJAN P, Curry JL, Ning J, Piao J, et al
    Tumor thickness and mitotic rate robustly predict melanoma-specific survival in patients with primary vulvar melanoma: A retrospective review of 100 cases.
    Clin Cancer Res. 2016 Nov 18. pii: clincanres.2126.2016.
    PubMed     Text format     Abstract available


  11. SANGIOLO D, Gammaitoni L, Giraudo L, Macagno M, et al
    Cytokine Induced Killer cells kill chemo-surviving melanoma cancer stem cells.
    Clin Cancer Res. 2016 Nov 4. pii: clincanres.1524.2016.
    PubMed     Text format     Abstract available


  12. KHALIL DN, Postow MA, Ibrahim N, Ludwig DL, et al
    An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma.
    Clin Cancer Res. 2016;22:5204-5210.
    PubMed     Text format     Abstract available


    August 2016
  13. ROSE AA, Annis MG, Frederick DT, Biondini M, et al
    MAPK Pathway Inhibitors Sensitize BRAF Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
    Clin Cancer Res. 2016 Aug 11. pii: clincanres.1192.2016.
    PubMed     Text format     Abstract available


  14. XI L, Pham T, Payabyab EC, Sherry RM, et al
    Circulating Tumor DNA as an Early Indicator of Response to T-Cell Transfer Immunotherapy in Metastatic Melanoma.
    Clin Cancer Res. 2016 Aug 1. pii: clincanres.0613.2016.
    PubMed     Text format     Abstract available


    June 2016
  15. CARLINO MS, Long GV
    Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?
    Clin Cancer Res. 2016 Jun 23. pii: clincanres.2944.2016.
    PubMed     Text format     Abstract available


  16. NIESSNER H, Schmitz J, Tabatabai G, Schmid A, et al
    PI3K pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo.
    Clin Cancer Res. 2016 Jun 15. pii: clincanres.0064.2016.
    PubMed     Text format     Abstract available


    May 2016
  17. WEIDE B, Martens A, Hassel JC, Berking C, et al
    Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab.
    Clin Cancer Res. 2016 May 16. pii: clincanres.0127.2016.
    PubMed     Text format     Abstract available


  18. SADE-FELDMAN M, Kanterman J, Klieger Y, Ish-Shalom E, et al
    Clinical significance of circulating CD33+CD11b+HLA-DR- myeloid cells in Stage-IV melanoma patients treated with ipilimumab.
    Clin Cancer Res. 2016 May 13. pii: clincanres.3104.2015.
    PubMed     Text format     Abstract available


  19. MARTENS A, Wistuba-Hamprecht K, Yuan J, Postow MA, et al
    Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab.
    Clin Cancer Res. 2016 May 11. pii: clincanres.0249.2016.
    PubMed     Text format     Abstract available


  20. OTT PA, Hodi FS
    Talimogene Laherparepvec for the Treatment of Advanced Melanoma.
    Clin Cancer Res. 2016 May 4. pii: clincanres.2709.2016.
    PubMed     Text format     Abstract available


    April 2016
  21. KREPLER C, Xiao M, Sproesser K, Brafford PA, et al
    Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
    Clin Cancer Res. 2016;22:1592-602.
    PubMed     Text format     Abstract available


    March 2016
  22. ANDERSEN R, Donia M, Ellebaek E, Borch TH, et al
    Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL-2 regimen.
    Clin Cancer Res. 2016 Mar 22. pii: clincanres.1879.2015.
    PubMed     Text format     Abstract available


  23. MADORE J, Strbenac D, Vilain R, Menzies AM, et al
    PD-L1 negative status is associated with lower mutation burden, differential expression of immune-related genes, and worse survival in stage-III melanoma.
    Clin Cancer Res. 2016 Mar 9. pii: clincanres.1714.2015.
    PubMed     Text format     Abstract available


  24. FIELD MG, Decatur CL, Kurtenbach S, Gezgin G, et al
    PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.
    Clin Cancer Res. 2016;22:1234-42.
    PubMed     Text format     Abstract available


  25. KOHLHAPP FJ, Kaufman HL
    Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
    Clin Cancer Res. 2016;22:1048-54.
    PubMed     Text format     Abstract available


    February 2016
  26. HARTSOUGH EJ, Aplin AE
    Of Mice and Melanoma: PDX System for Modeling Personalized Medicine.
    Clin Cancer Res. 2016 Feb 3. pii: clincanres.3054.2016.
    PubMed     Text format     Abstract available


  27. CHARYCH DH, Hoch U, Langowski JL, Lee SR, et al
    NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.
    Clin Cancer Res. 2016;22:680-90.
    PubMed     Text format     Abstract available


    January 2016
  28. MARTENS A, Wistuba-Hamprecht K, Geukes Foppen MH, Yuan J, et al
    Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab.
    Clin Cancer Res. 2016 Jan 19. pii: clincanres.2412.2015.
    PubMed     Text format     Abstract available


  29. EKMEKCIOGLU S, Davies MA, Tanese K, Roszik J, et al
    Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and its Expression Associates with Favorable Survival for Stage III Melanoma.
    Clin Cancer Res. 2016 Jan 18. pii: clincanres.2226.2015.
    PubMed     Text format     Abstract available


  30. VOGELSANG M, Martinez CN, Rendleman J, Bapodra AB, et al
    The expression quantitative trait loci in immune pathways and their effect on cutaneous melanoma prognosis.
    Clin Cancer Res. 2016 Jan 5. pii: clincanres.2066.2015.
    PubMed     Text format     Abstract available


    December 2015
  31. ROTHERMEL LD, Sabesan A, Stephens DJ, Chandran SS, et al
    Identification of an immunogenic subset of metastatic uveal melanoma.
    Clin Cancer Res. 2015 Dec 28. pii: clincanres.2294.2015.
    PubMed     Text format     Abstract available


  32. SCHREIBELT G, Bol KF, Westdorp H, Wimmers F, et al
    Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells.
    Clin Cancer Res. 2015 Dec 28. pii: clincanres.2205.2015.
    PubMed     Text format     Abstract available


  33. DAVAR D, Kirkwood JM
    CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma-Kinase Inhibition Redux.
    Clin Cancer Res. 2015;21:5412-5414.
    PubMed     Text format     Abstract available


  34. PIRES SILVA I, Salhi A, Giles KM, Vogelsang M, et al
    Identification of a novel pathogenic germline KDR variant in melanoma.
    Clin Cancer Res. 2015 Dec 2. pii: clincanres.1811.2015.
    PubMed     Text format     Abstract available


    November 2015
  35. HOOS A, Wolchok JD, Humphrey RW, Hodi FS, et al
    CCR 20th Anniversary Commentary: Immune-Related Response Criteria--Capturing Clinical Activity in Immuno-Oncology.
    Clin Cancer Res. 2015;21:4989-91.
    PubMed     Text format     Abstract available


    October 2015
  36. LEGAT A, Maby-El Hajjami H, Baumgaertner P, Cagnon L, et al
    Vaccination with LAG-3Ig (IMP321) and peptides induces specific CD4 and CD8 T-cell responses in metastatic melanoma patients - report of a phase I/IIa clinical trial.
    Clin Cancer Res. 2015 Oct 23. pii: clincanres.1212.2015.
    PubMed     Text format     Abstract available


  37. ZABOR EC, Heller G, Schwartz LH, Chapman PB, et al
    Correlating surrogate endpoints with overall survival at the individual patient level in BRAFV600E-mutated metastatic melanoma patients treated with vemurafenib.
    Clin Cancer Res. 2015 Oct 21. pii: clincanres.1441.2015.
    PubMed     Text format     Abstract available


  38. KONG Y, Si L, Li Y, Wu X, et al
    Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.
    Clin Cancer Res. 2015 Oct 21. pii: clincanres.1110.2015.
    PubMed     Text format     Abstract available


  39. JACKSON CM, Kochel CM, Nirschl CJ, Durham NM, et al
    Systemic Tolerance Mediated by Melanoma Brain Tumors is Reversible by Radiotherapy and Vaccination.
    Clin Cancer Res. 2015 Oct 21. pii: clincanres.1516.2015.
    PubMed     Text format     Abstract available


  40. FREEMAN-KELLER M, Kim Y, Cronin H, Richards A, et al
    Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.
    Clin Cancer Res. 2015 Oct 7. pii: clincanres.1136.2015.
    PubMed     Text format     Abstract available


  41. GRANGE JM, Krone B
    Ancient Retrovirus Targeted by Engineered T Cells in Melanoma-Letter.
    Clin Cancer Res. 2015;21:4494.
    PubMed     Text format    


    August 2015
  42. WILSON MA, Zhao F, Khare S, D'Andrea K, et al
    Copy number changes are associated with response to treatment with carboplatin, paclitaxel, and sorafenib in melanoma.
    Clin Cancer Res. 2015 Aug 25. pii: clincanres.1162.2015.
    PubMed     Text format     Abstract available


  43. GEBHARDT C, Sevko A, Jiang H, Lichtenberger R, et al
    Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab.
    Clin Cancer Res. 2015 Aug 19. pii: clincanres.0676.2015.
    PubMed     Text format     Abstract available


    July 2015
  44. ANDREWS MC, Turner N, Boyd J, Roberts AW, et al
    Cellular mechanisms underlying complete hematological response of chronic myeloid leukemia to BRAF/MEK inhibition in a patient with concomitant metastatic melanoma.
    Clin Cancer Res. 2015 Jul 22. pii: clincanres.0393.2015.
    PubMed     Text format     Abstract available


  45. HONG D, Kurzrock R, Wheler JJ, Naing A, et al
    Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma.
    Clin Cancer Res. 2015 Jul 13. pii: clincanres.3063.2015.
    PubMed     Text format     Abstract available


  46. LIU Y, Hawkins OE, Vilgelm AE, Pawlikowski JS, et al
    Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.
    Clin Cancer Res. 2015 Jul 7. pii: clincanres.0293.2015.
    PubMed     Text format     Abstract available


    June 2015
  47. HANNIFORD D, Zhong J, Koetz L, Gaziel-Sovran A, et al
    A miRNA-based signature detected in primary melanoma tissue predicts development of brain metastasis.
    Clin Cancer Res. 2015 Jun 18. pii: clincanres.2566.2014.
    PubMed     Text format     Abstract available


  48. SULLIVAN RJ, Flaherty KT
    New strategies in melanoma: entering the era of combinatorial therapy.
    Clin Cancer Res. 2015;21:2424-35.
    PubMed     Text format     Abstract available


  49. BOWERS JS, Nelson MH, Kundimi S, Bailey SR, et al
    Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling.
    Clin Cancer Res. 2015;21:2546-57.
    PubMed     Text format     Abstract available


    May 2015
  50. REED CM, Cresce ND, Mauldin IS, Slingluff CL Jr, et al
    Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival.
    Clin Cancer Res. 2015 May 12. pii: clincanres.0233.2015.
    PubMed     Text format     Abstract available


  51. TAUBE JM, Young GD, McMiller TL, Chen S, et al
    Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade.
    Clin Cancer Res. 2015 May 5. pii: clincanres.0244.2015.
    PubMed     Text format     Abstract available


  52. CARSON CC, Moschos SJ, Edmiston SN, Darr DB, et al
    IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma.
    Clin Cancer Res. 2015;21:2167-76.
    PubMed     Text format     Abstract available


    April 2015
  53. SULLIVAN RJ, Flaherty KT
    Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma.
    Clin Cancer Res. 2015 Apr 30. pii: clincanres.3061.2014.
    PubMed     Text format     Abstract available


    March 2015
  54. COOPER LJ, Krishnamurthy J, Rabinovich B, Mi T, et al
    Genetic Engineering of T cells to Target HERV-K, an Ancient Retrovirus on Melanoma.
    Clin Cancer Res. 2015 Mar 31. pii: clincanres.3197.2014.
    PubMed     Text format     Abstract available


  55. KLUGER H, Zito CR, Barr M, Baine M, et al
    Characterization of PD-L1 Expression and Associated T cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.
    Clin Cancer Res. 2015 Mar 18. pii: clincanres.3073.2014.
    PubMed     Text format     Abstract available


  56. RODRIGUEZ-GARCIA A, Gimenez-Alejandre M, Rojas JJ, Moreno R, et al
    Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression.
    Clin Cancer Res. 2015;21:1406-18.
    PubMed     Text format     Abstract available


  57. ROBBINS PF, Kassim SH, Tran TL, Crystal JS, et al
    A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.
    Clin Cancer Res. 2015;21:1019-27.
    PubMed     Text format     Abstract available


    February 2015
  58. CARVAJAL RD, Lawrence DP, Weber J, Gajewski TF, et al
    Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.
    Clin Cancer Res. 2015 Feb 18. pii: clincanres.1630.2014.
    PubMed     Text format     Abstract available


  59. ZHANG L, Morgan RA, Beane JD, Zheng Z, et al
    Tumor Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma.
    Clin Cancer Res. 2015 Feb 18. pii: clincanres.2085.2014.
    PubMed     Text format     Abstract available


  60. MIN L, Hodi FS, Giobbie-Hurder A, Ott PA, et al
    Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study.
    Clin Cancer Res. 2015;21:749-55.
    PubMed     Text format     Abstract available


  61. CHACON JA, Sarnaik AA, Chen JQ, Creasy C, et al
    Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.
    Clin Cancer Res. 2015;21:611-21.
    PubMed     Text format     Abstract available


    January 2015
  62. WANG T, Xiao M, Ge Y, Krepler C, et al
    BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth.
    Clin Cancer Res. 2015 Jan 23. pii: clincanres.1554.2014.
    PubMed     Text format     Abstract available


  63. SCOLYER RA, Kakavand H, Wilmott JS, Menzies AM, et al
    PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients.
    Clin Cancer Res. 2015 Jan 21. pii: clincanres.2023.2014.
    PubMed     Text format     Abstract available


  64. LASSEN UN, Meulendijks D, Siu LL, Karanikas V, et al
    A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers.
    Clin Cancer Res. 2015;21:258-66.
    PubMed     Text format     Abstract available


  65. GERAMI P, Cook RW, Wilkinson J, Russell MC, et al
    Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma.
    Clin Cancer Res. 2015;21:175-83.
    PubMed     Text format     Abstract available


    December 2014
  66. GIBNEY GT, Kudchadkar RR, DeConti RC, Thebeau MS, et al
    Safety, correlative markers and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.
    Clin Cancer Res. 2014 Dec 18. pii: clincanres.2468.2014.
    PubMed     Text format     Abstract available


  67. HUTCHINSON KE, Ross JS, Stephens PJ, Miller VA, et al
    Melanoma BRAF Fusions-Response.
    Clin Cancer Res. 2014;20:6632.
    PubMed     Text format    


  68. BOTTON T, Yeh I, Bastian BC
    Melanoma BRAF Fusions-Letter.
    Clin Cancer Res. 2014;20:6631.
    PubMed     Text format    


    November 2014
  69. CHANDRAN SS, Paria BC, Srivastava AK, Rothermel LD, et al
    Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans.
    Clin Cancer Res. 2014 Nov 25. pii: clincanres.2208.2014.
    PubMed     Text format     Abstract available


  70. CARLINO MS, Fung C, Shahheydari H, Todd JR, et al
    Pre-existing MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.
    Clin Cancer Res. 2014 Nov 4. pii: clincanres.0759.2014.
    PubMed     Text format     Abstract available


    May 2014
  71. JOHNSON GL, Stuhlmiller TJ, Angus SP, Zawistowski JS, et al
    Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
    Clin Cancer Res. 2014;20:2516-22.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: